Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 6.89B 6.05B 5.63B 5.17B 9.71B 664B 9.86B 66.85B 26.12B 326B 25.88B 25.32B 1,128B P/E 2026 *
-7.23x
P/E 2027 * -173x
Enterprise Value 6.93B 6.08B 5.66B 5.19B 9.76B 667B 9.91B 67.19B 26.25B 328B 26.01B 25.45B 1,134B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 8.38x
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.16%
1 week-4.90%
Current month-3.45%
1 month-1.69%
3 months+23.54%
6 months+19.87%
Current year+43.09%
1 week 109.75
Extreme 109.75
120.54
1 month 109.75
Extreme 109.75
130
Current year 73.82
Extreme 73.82
130
1 year 50.25
Extreme 50.25
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Sell

Chief Financial Officer

-5,000 0.0082%
7/6/26 Fiscal year

Founder

60,000 0.0984%
7/1/26 Sell

Controller/Auditor

-2,721 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-1.16%-4.90%+116.66%+357.06% 6.89B
+0.86%+1.43%+48.50%+160.39% 1,067B
+1.59%+4.09%+55.34%+53.96% 635B
+0.95%+1.91%+35.91%+81.14% 458B
+1.60%+6.25%+33.95%+29.84% 347B
-0.60%+1.52%+35.68%+39.76% 295B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 216B
+1.22%+2.66%+21.87%+59.73% 203B
-1.18%-3.70%+14.23%+66.51% 161B
Average +0.22%+0.70%+35.00%+82.42% 364.99B
Weighted average by Cap. +0.54%+1.94%+35.97%+78.20%

Financials

2026 *2027 *
Net sales 675M 593M 552M 506M 951M 65.03B 966M 6.55B 2.56B 31.97B 2.54B 2.48B 111B 815M 716M 666M 611M 1.15B 78.5B 1.17B 7.91B 3.09B 38.59B 3.06B 2.99B 133B
Net income -910M -799M -743M -682M -1.28B -87.61B -1.3B -8.82B -3.45B -43.07B -3.42B -3.34B -149B -1.62M -1.42M -1.32M -1.22M -2.28M -156M -2.32M -15.73M -6.15M -76.8M -6.09M -5.96M -266M
Net Debt 34.69M 30.47M 28.33M 26M 48.85M 3.34B 49.6M 336M 131M 1.64B 130M 127M 5.68B -61.06M -53.63M -49.88M -45.77M -85.99M -5.88B -87.32M -592M -231M -2.89B -229M -224M -10B
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
418
Date Price Change Volume
26-07-24 US$113.03 -1.16% 516,940
26-07-23 US$114.36 -0.10% 1,403,720
26-07-22 US$114.48 -2.20% 441,965
26-07-21 US$117.05 +0.37% 619,528
26-07-20 US$116.62 -1.88% 365,743
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
113.03USD
Average target price
146.50USD
Spread / Average Target
+29.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIRM Stock